Вид документа : Статья из журнала Шифр издания : Автор(ы) : Kolte R. Заглавие : Adverse effects following COVID-19 vaccination in India: a cross-sectional study Место публикации : Український науково-медичний молодіжний журнал. - 2022. - № 3 спецвип. - С. 78 (Шифр УУ14/2022/3 спецвип.) MeSH-главная: ИНДИЯ -- INDIA КОРОНАВИРУСНЫЕ ИНФЕКЦИИ -- CORONAVIRUS INFECTIONS ВАКЦИНАЦИЯ МАССОВАЯ -- MASS VACCINATION ПОБОЧНЫЕ ЭФФЕКТЫ И НЕБЛАГОПРИЯТНЫЕ РЕАКЦИИ, СВЯЗАННЫЕ С ЛЕКАРСТВАМИ -- DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS Аннотация: The COVID-19 pandemic has caused not only significant morbidity and mortality throughout the world, but major social, educational and economic disruptions as well. COVID-19 vaccination remains main preventive measure to control the infection by archiving herd immunity. However, several adverse effects associated with COVID-19 vaccination were reported, which creates favorable conditions for vaccination hesitancy. In this study we aimed to investigate the adverse effects and safety of COVID-19 vaccination. Ат: To identify the adverse effects of COVID-19 vaccination. To find out association of adverse effects of COVID-19 vaccination with socio-demographic variables. Materials and methods: We conducted an observational non-interventional study with purposive sampling technique. An online questionnaire was designed using Google forms which was shared via social media with consent form. By using the questionnaire, we collected 279 responses from people who received at least one dose of COVID-19 vaccination during 06/09/21 to 07/10/21 in different vaccination centres in India. Socio-demographic data like age, gender, place of residence, education, occupation, any morbid condition, as well as type of adverse effects and the time of their onset, were collected. The data was then analysed and descriptive statistics were presented by number and percentage for categorical variables. Chi-square test and logistic regression were used to assess the association of socio-demographic parameters with appearance of adverse events following vaccination with significance level of p-value being less than 0.05